Tavapadon Followed by Tavapadon + Carbamazepine for Parkinson's Disease

"This trial is open to 16 people aged between 18 and 55 who have been diagnosed with Parkinson's disease. Furthermore, they must be nonchildbearing women or sexually active men of childbearing potential that agree to use condoms; their body mass index needs to fall within the range of 18.5-32 kg/m2 (with a total weight above 50kg) as well as demonstrate overall health through medical evaluation including physical examination, ECG etc.; finally participants need to understand the nature of this research and comply with all protocol requirements such as dosage regimens, follow up visits etc."

"Clinicaltrials.gov suggests that this clinical trial is still searching for participants, as the original post date was October 19th 2022 and it has been recently edited on November 3rd of the same year."

"There is limited evidence of tavapadon, in combination with carbamazepine's safety and efficacy; therefore, the assessment score was a 1."

"This trial has an age requirement of 18 to 55 years old. For those younger than the required age, there are 27 studies available and 482 for those exceeding the upper limit."

"Affirmative. The information on clinicaltrials.gov suggests this medical trial is still recruiting patients, and was first posted on October 19th 2022. Subsequently, it was last modified November 3rd 2022 and requires 16 participants from one location to be enrolled."